The role of mesalamine in the treatment of ulcerative colitis

References

• ArdizzoneSMaconiGRussoARandomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitsGut200555475315972298
   PubMed Web of Science ®Google Scholar
• BernsteinCNBlanchardJFKliewerCancer risk in patients with inflammatory bowel disease: population based studyCancer2001918546211241255
   PubMed Web of Science ®Google Scholar
• BernsteinCNRawsthornePCheangMA population-based case control study of potential risk factors for IBDAm J Gastroenterol2006101993100216696783
   PubMed Web of Science ®Google Scholar
• BonenDKChoJHThe genetics of inflammatory bowel diseaseGastroenterology20031245213612557156
   PubMed Web of Science ®Google Scholar
• BusPJNagtegaalIDVerspagetMesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era?Aliment Pharmacol Ther199913139740210571594
   PubMed Web of Science ®Google Scholar
• CohenRDReview article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitisAliment Pharmacol Ther2006244657416886912
   PubMed Web of Science ®Google Scholar
• CohenRDWosethDMThistedRAA Meta-analysis and overview of the Literature on Treatment Options for Left-Sided Ulcerative Colitis and Ulcerative ProctitisAm J Gastroenterol20009512637610811338
   PubMed Web of Science ®Google Scholar
• ColombelJFBrabantGGublrtMCRenal Insufficiency in infant: Side effect of prenatal exposure to meslazine?Lancet199434462017914992
   PubMed Web of Science ®Google Scholar
• CunliffeRNScottBBMonitoring for drug side-effects in inflammatory bowel diseaseAliment Pharmacol Ther2002166476211929382
   PubMed Web of Science ®Google Scholar
• D’ArienzoAMangusoFCiminoLBeclomethasone dipropionate (3 mg) enemas combined with oral 5-ASAs (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA aloneItal J Gastroenterol Hepatol19983025479759590
   PubMed Web of Science ®Google Scholar
• Diav-CitranOParkYWVeerasuntharanGThe safety of Mesalamine in Human Pregnancy: A Prospective Controlled Cohort StudyGastroenterology19981142389428214
   PubMed Web of Science ®Google Scholar
• EganLJMaysDCHuntoonCJInhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activityJ Biol Chem199927444853
   Web of Science ®Google Scholar
• FiocchiCInflammatory bowel disease: etiology and pathogenesisGastroenterology19981151822059649475
   PubMed Web of Science ®Google Scholar
• FrieriGPimpoMGallettiLong-term oral plus topical mesalazine in frequently relapsing ulcerative colitisDigestive and Liver Disease20053792615733520
   PubMed Web of Science ®Google Scholar
• GrishamMDOxidants and free radicals in inflammatory bowel diseaseLancet1994344859617916405
   PubMed Web of Science ®Google Scholar
• HanauerSBReview article: aminosalicylates in inflammatory bowel ulcerative colitisAliments Pharmacol Ther200420Suppl 4605
   PubMed Web of Science ®Google Scholar
• HanauerSBSandbornWJKornbluthADelayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active disease. Ascend II TrialAmerican Journal of Gastroenterology200510024788516279903
   PubMed Web of Science ®Google Scholar
• KaiserGCYanFPolkDBMesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytesGastroenterology1999116602910029619
   PubMed Web of Science ®Google Scholar
• KaneSVBjorkmanDJThe efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: A Systematic ReviewReviews in Gastroenterological Disorders200332101814668693
   PubMedGoogle Scholar
• KornbluthASacharDUlcerative Colitis Practice Guidelines in adults (Update): American College of Gastroenterology, Practice Parameters CommitteeAmerican Journal of Gastroenerology2004137285
   Google Scholar
• LoftusEVSilverstein SandbornWJUlcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survivialGut2000463364310673294
   PubMed Web of Science ®Google Scholar
• LoftusEVKaneSVBjorkmanDSystematic review: short-term adverse effects of 5-aminosalicylic acid in the treatment of ulcerative colitisAliment Pharmacol Ther2003191798914723609
   PubMed Web of Science ®Google Scholar
• MansfieldJCGiafferMHCannPAA double-blind comparison of balsalazide, 6.75 g and sulfasalazine, 3 g as sole therapy in the management of ulcerative colitisAliment Pharmacol Ther200216697711856080
   PubMed Web of Science ®Google Scholar
• MarshallJKIrvineEJRectal aminosalicylate therapy for distal ulcerative colitis: a meta analysisAliment Pharmacol Ther199592933007654892
   PubMed Web of Science ®Google Scholar
• MarteauPHProbertCSLindgrenMCombined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomized, double blind placebo controlled studyGut200554960515951542
   PubMed Web of Science ®Google Scholar
• MarteauPHCrandJFoucaultMUse of mesalazine slow release suppositories 1 gm three times per week to maintain remission of ulcerative proctitis: a randomized double blind placebo controlled multicentre studyGut19984219599536943
   PubMed Web of Science ®Google Scholar
• MarteauPHSeksikBeaugerieRecommandations pour la pratique clinique pour le traitment de la rectocolite hemorragiqueGastroenterol Clin Biol2004289556015672566
   PubMedGoogle Scholar
• MisiewiczJJLennardJonesJEControlled trial of sulphasalazine in maintenance therapy for ulcerative colitisLancet196511858
   Web of Science ®Google Scholar
• OrholmMMunkholmPLangholzEFamilial occurrence of inflammatory bowel diseaseN Eng J Med1991324848
   PubMed Web of Science ®Google Scholar
• PaoluziOAIacopiniFPicaPComparison of two different daily dosages (2.4 vs 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up studyAliment Pharmacol Ther2005211111915854173
   PubMed Web of Science ®Google Scholar
• PodoloskyDKInflammatory Bowel DiseaseN Eng J Med200234741729
   PubMed Web of Science ®Google Scholar
• Powell-TuckJTrueloveSCThe course and prognosis of ulcerative colitisGut1963429931514084741
   PubMed Web of Science ®Google Scholar
• PowrieFT-cells in inflammatory bowel disease: protective and pathogenic rolesImmunity1995317147648390
   PubMed Web of Science ®Google Scholar
• PranteraCViscidoABianconeLA new oral delivery system for 5-ASA: preliminary clinical findings for MMXInflamm Bowel Dis200511421715867580
   PubMed Web of Science ®Google Scholar
• PruittRHansonJSafdiMBalsalazide is superior to mesalamine in time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitisAm J Gastroenterol20029730788612492193
   PubMed Web of Science ®Google Scholar
• RansfordRALangmanMJSulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of MedicinesGut200251536912235076
   PubMed Web of Science ®Google Scholar
• RochesterJAbreuMTUlcerative Colitis Therapy: Importance of Delivery MechanismsReviews in Gastroenterological Disorders200552152216369217
   PubMedGoogle Scholar
• Reinacher-SchickASeidenstickerFPetrashSMesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowelEndoscopy2000322455410718391
   PubMed Web of Science ®Google Scholar
• RubinDTLoSavioAYardonNAminosalicylate Therapy in the Prevention of Dysplasia and Colorectal Cancer in Ulcerative ColitisClinical Gastroenterology and Hepatology2006413465017059900
   PubMed Web of Science ®Google Scholar
• SafdiMDeMiccoMSninskyCAA double-blind comparison of oral versus rectal mesalamine combination therapy in treatment of distal ulcerative colitisAm J Gastroenterol1997921867719382054
   PubMed Web of Science ®Google Scholar
• SchroederKWTremaineWJIlstrupCoated oral 5-aminosalicylic acid therapy for mild to moderately active ulcerative colitisN Engl J Med198717162593317057
   PubMed Web of Science ®Google Scholar
• ShanahanFInflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeuticsGastroenterology20011206223511179240
   PubMed Web of Science ®Google Scholar
• SninskyCACortDHShanahanFOral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter trialAnn Intern Med199111535051863024
   PubMed Web of Science ®Google Scholar
• StensonWFKorzenikWYamataTInflammatory Bowel DiseaseTextbook of Gastroenterology20034Lippincott Williams and Wilkins1699759
   Google Scholar
• StroberWLudvikssonBRFussIJThe pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn’s diseaseAnn Intern Med1998128848569599198
   PubMed Web of Science ®Google Scholar
• SutherlandLMacdonaldJKOral 5-aminosalicylates for induction of remission in ulcerative colitisCochrane Database2006
   Web of Science ®Google Scholar
• van StaaTPCardTLoganRF5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological studyGut2005541573815994215
   PubMed Web of Science ®Google Scholar
• VelayosFSTerdimanJPWalshJMEffect of 5-aminosalicylastes use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studiesAm J Gastroenterol200510013455315929768
   PubMed Web of Science ®Google Scholar